- Home
- STTK vs PODC Comparison
STTK vs PODC Comparison
Compare STTK & PODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PODC
- Stock Information
- Founded
- STTK 2016
- PODC 2013
- Country
- STTK United States
- PODC United States
- Employees
- STTK N/A
- PODC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PODC
- Sector
- STTK Health Care
- PODC
- Exchange
- STTK Nasdaq
- PODC Nasdaq
- Market Cap
- STTK 37.6M
- PODC 44.1M
- IPO Year
- STTK 2020
- PODC N/A
- Fundamental
- Price
- STTK $0.83
- PODC $2.33
- Analyst Decision
- STTK Hold
- PODC
- Analyst Count
- STTK 4
- PODC 0
- Target Price
- STTK $3.00
- PODC N/A
- AVG Volume (30 Days)
- STTK 401.8K
- PODC 109.5K
- Earning Date
- STTK 07-31-2025
- PODC 08-12-2025
- Dividend Yield
- STTK N/A
- PODC N/A
- EPS Growth
- STTK N/A
- PODC N/A
- EPS
- STTK N/A
- PODC N/A
- Revenue
- STTK $4,606,000.00
- PODC $52,119,000.00
- Revenue This Year
- STTK N/A
- PODC $19.39
- Revenue Next Year
- STTK N/A
- PODC $23.41
- P/E Ratio
- STTK N/A
- PODC N/A
- Revenue Growth
- STTK 69.65
- PODC 20.36
- 52 Week Low
- STTK $0.69
- PODC $1.10
- 52 Week High
- STTK $4.99
- PODC $2.94
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- PODC 53.21
- Support Level
- STTK $0.77
- PODC $2.25
- Resistance Level
- STTK $0.91
- PODC $2.94
- Average True Range (ATR)
- STTK 0.08
- PODC 0.30
- MACD
- STTK -0.02
- PODC 0.04
- Stochastic Oscillator
- STTK 16.23
- PODC 45.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.